Novo Nordisk A/S $NVO Shares Acquired by Smith Chas P & Associates PA Cpas

Smith Chas P & Associates PA Cpas boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 105.3% in the 3rd quarter, Holdings Channel reports. The firm owned 405,425 shares of the company’s stock after buying an additional 207,959 shares during the quarter. Novo Nordisk A/S accounts for approximately 1.9% of Smith Chas P & Associates PA Cpas’ portfolio, making the stock its 20th biggest position. Smith Chas P & Associates PA Cpas’ holdings in Novo Nordisk A/S were worth $22,497,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in NVO. Insigneo Advisory Services LLC grew its stake in shares of Novo Nordisk A/S by 5.7% in the third quarter. Insigneo Advisory Services LLC now owns 25,467 shares of the company’s stock valued at $1,413,000 after buying an additional 1,368 shares in the last quarter. Level Four Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S by 0.3% during the 3rd quarter. Level Four Advisory Services LLC now owns 159,807 shares of the company’s stock valued at $8,868,000 after buying an additional 423 shares during the period. Teachers Retirement System of The State of Kentucky lifted its position in Novo Nordisk A/S by 5.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 60,940 shares of the company’s stock worth $3,382,000 after acquiring an additional 3,200 shares in the last quarter. Focus Partners Advisor Solutions LLC boosted its holdings in Novo Nordisk A/S by 26.8% in the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 9,281 shares of the company’s stock worth $515,000 after acquiring an additional 1,963 shares during the period. Finally, Round Hill Asset Management grew its position in Novo Nordisk A/S by 32.8% in the third quarter. Round Hill Asset Management now owns 75,725 shares of the company’s stock valued at $4,202,000 after acquiring an additional 18,686 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research note on Tuesday. Finally, Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Five research analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $53.93.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley upgraded NVO to Equal-weight, arguing the recent sell-off better prices mid‑term risks; they set a $40 target. Morgan Stanley upgrade
• Positive Sentiment: Novo announced large Ireland investments and facility upgrades (combined ~€432m–$506m / $372.5m project) to expand Wegovy/oral production capacity — a defensive move to protect market share versus Eli Lilly. Ireland investment/CNBC
• Positive Sentiment: Company disclosed progress on its 2026 share buyback programme, which supports buy-side demand and EPS accretion over time. Buyback progress
• Neutral Sentiment: The Goldman Sachs team reaffirmed a “Neutral” rating but cut its price target to $41 (from $63), signaling tempered expectations even as they stop short of a downgrade. Goldman Sachs note
• Neutral Sentiment: Roche says it aims for double-digit share in the weight‑loss market, highlighting intensifying competition but not an immediate commercial impact. Roche competition
• Negative Sentiment: The U.S. FDA ordered Novo to stop a consumer Ozempic ad for being false/misleading — the agency’s second such warning and a reputational/regulatory headache that can affect marketing and demand. FDA warning
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Novo — potential litigation risk that can increase scrutiny and legal costs. Investor investigation
• Negative Sentiment: Aspen expects a Canadian approval this year for a generic targeting Ozempic, adding potential price competition and margin pressure in important markets. Generic Ozempic risk
• Negative Sentiment: Novo said it will halve U.S. list price of Wegovy in 2027, which should protect access but will compress revenues and signal pricing pressure in obesity drugs. Wegovy price cut
• Negative Sentiment: Market attention to Eli Lilly’s clinical wins and new entrants has driven sharp recent share weakness — an ongoing competitive threat to GLP‑1 pricing and volumes. Lilly competition

Novo Nordisk A/S Stock Down 2.9%

NVO opened at $36.68 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The company has a market capitalization of $163.78 billion, a PE ratio of 10.57 and a beta of 0.73. The stock’s fifty day moving average is $52.24 and its 200-day moving average is $52.68. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $91.90.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.